Kubota Y, Miura T, Shuin T, Kinoshita Y, Hosaka M, Kondo I, Moriyama M, Fukushima S, Fukuoka H, Miyai K
Dept. of Urology, Yokohama City University School of Medicine.
Gan To Kagaku Ryoho. 1991 Oct;18(13):2301-6.
A cooperative phase II study of 5'-DFUR at a daily dose of 800 to 1,200 mg was performed on 18 patients with bladder cancer. The therapeutic responses were evaluated by Koyama-Saito's criteria in 13 out of 18 patients, and 3 PR, 1 MR, 6 NC and 3 PD were obtained. Adverse reactions were observed in three out of 15 cases (20.0%). These side effects were reversible gastrointestinal symptoms such as nausea-vomiting, anorexia and diarrhea. The results suggest that 5'-DFUR is a useful drug for bladder cancer treatment.
对18例膀胱癌患者进行了一项5'-DFUR每日剂量为800至1200毫克的II期合作研究。18例患者中有13例根据小山-斋藤标准评估治疗反应，获得3例部分缓解（PR）、1例轻度缓解（MR）、6例病情稳定（NC）和3例病情进展（PD）。15例中有3例（20.0%）观察到不良反应。这些副作用是可逆的胃肠道症状，如恶心呕吐、食欲不振和腹泻。结果表明，5'-DFUR是一种治疗膀胱癌的有效药物。
